Guiding CAR Cell Therapy by Antibodies

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: closed (31 August 2018) | Viewed by 369

Special Issue Editor

Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, PA 15213, USA
Interests: therapeutic antibodies; human antibodies and their interactions; vaccine immunogens; molecular engineering; screening and sequencing methodologies; therapeutic proteins; cancer; infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recently, T cells armed with chimeric antigen receptors (CARs) guided by antibodies have emerged as a promising approach to fight cancer and other diseases. The design of CARs has evolved, but the success of the therapy is contingent upon the combination of robust therapeutics efficacy and enhanced tumor selectivity, with minimal on-target off tumor activity. Several studies have indicated that both the affinity of the antibody and the specificity of its epitope are important components in CAR T cell activity. Other components of the CARs including costimulatory molecules and extracellular spacers are also important. Given the importance of each of these components and the complexity of the T cell receptor interactions and CARs with their targets empirical determination will likely be required to identify the optimal CAR T cell design for any given target. Similarly, natural killer (NK) cells and other cells expressing CARs should be evaluated for efficacy and specificity.

This Special Issue of Antibodies focuses on new research developments of CARs, and especially as related to antibodies.

Prof. Dr. Dimiter S. Dimitrov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Chimeric antigen receptors (CARs)
  • Cancer and tumor therapy
  • Tumor selectivity
  • Optimal CAR T cell design
  • CAR T cell Activity

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop